S
Shuangni Yu
Researcher at Peking Union Medical College Hospital
Publications - 55
Citations - 1388
Shuangni Yu is an academic researcher from Peking Union Medical College Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 14, co-authored 31 publications receiving 1157 citations. Previous affiliations of Shuangni Yu include Peking Union Medical College.
Papers
More filters
Journal ArticleDOI
miRNA-96 Suppresses KRAS and Functions as a Tumor Suppressor Gene in Pancreatic Cancer
Shuangni Yu,Zhaohui Lu,Changzheng Liu,Yunxiao Meng,Yihui Ma,Wugan Zhao,Jian-Ping Liu,Jia Yu,Jie Chen +8 more
TL;DR: It is reported that miR-96 directly targets the KRAS oncogene and functions as a tumor-suppressing miRNA in pancreatic cancer cells and is identified as a potent regulator of KRAS.
Journal ArticleDOI
The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS.
TL;DR: It is concluded that the frequently downregulated miR-217 can regulate KRAS and function as a tumor suppressor in PDAC and may serve as a useful therapeutic agent for miRNA-based PDAC therapy.
Journal ArticleDOI
miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2.
TL;DR: The data reported here are the first to indicate that miR-27a plays an oncogenic role by targeting Spry2 and modulating the malignant, biological behavior of pancreatic cancer cells.
Journal ArticleDOI
Long noncoding RNA MIR31HG exhibits oncogenic property in pancreatic ductal adenocarcinoma and is negatively regulated by miR-193b
Haiyan Yang,Liu P,Jun-Wu Zhang,Xiaozhong Peng,Zhaohui Lu,Shuangni Yu,Yunxiao Meng,Wei-Min Tong,Jie Chen +8 more
TL;DR: It is demonstrated that MIR31HG functions as an oncogenic lncRNAs that promotes tumor progression, and miR-193b targets not only protein-coding genes but also the lncRNA, MIR 31HG.
Journal ArticleDOI
Ezrin promotes invasion and metastasis of pancreatic cancer cells
TL;DR: It is proposed that ezrin might play functional roles in modulating morphology, growth, motility and invasion of pancreatic cancer cells, and that the Erk1/2 pathway may be involved in these roles.